In 2023, the sale of respiratory system medicine in Canada stood at a substantial baseline, setting the stage for forecasted growth. From 2024 to 2028, sales are projected to increase from 2.74 billion Canadian Dollars to 3.09 billion, marking an incremental year-on-year growth. This continuous rise suggests a stable demand and a positive market outlook with a compound annual growth rate (CAGR) reflecting consistent expansion over this five-year period.
Future trends to watch for include:
- Evolving healthcare policies in Canada that might affect drug pricing and accessibility.
- Technological advancements in respiratory medicine leading to new treatments.
- Impact of demographic changes, including an aging population and increased incidence of respiratory conditions such as asthma and COPD.
- Potential disruptions or opportunities due to global events, such as pandemics or supply chain issues impacting pharmaceutical distribution.
